Search results for "Urology & Nephrology"

showing 10 items of 361 documents

Clinical Approach to Vascular Calcification in Patients With Non-dialysis Dependent Chronic Kidney Disease: Mineral-Bone Disorder-Related Aspects

2021

Chronic kidney disease (CKD) is associated with a very high morbimortality, mainly from cardiovascular origin, and CKD is currently considered in the high- or very high risk- cardiovascular risk category. CKD-mineral and bone disorders (CKD-MBDs), including vascular and/or valvular calcifications, are also associated with these poor outcomes. Vascular calcification (VC) is very prevalent (both intimal and medial), even in non-dialysis dependent patients, with a greater severity and more rapid progression. Simple X-ray based-scores such as Adragão's (AS) are useful prognostic tools and AS (even AS based on hand-X-ray only) may be superior to the classic Kauppila's score when evaluating non-d…

OncologyMedicine (General)medicine.medical_specialtyMini Review030232 urology & nephrologyParathyroid hormonePhosphate030204 cardiovascular system & hematologyCalcificationcalcification03 medical and health sciencesR5-9200302 clinical medicineInternal medicineVitamin D and neurologymedicineCKDCKD-MBDVascular calcificationphosphateVascular calcificationCalciprotein particlesSurrogate endpointbusiness.industryIncidence (epidemiology)General Medicinemedicine.diseasePathophysiologyvascular calcificationInsuficiència renal crònicaMedicinecalciprotein particlesbusinessCalcificationKidney diseaseFrontiers in Medicine
researchProduct

2017

Renal cell carcinoma (RCC) comprises a heterogenous group of tumors. Traditionally, papillary RCC (pRCC) is associated with a favorable outcome compared to clear cell RCC (ccRCC), while other series report equivalent or worse prognosis. In this paper we comparatively evaluate outcome of pRCC versus ccRCC in two large multi-institutional databases (cohort study), including distribution of pRCC subtypes 1 and 2. Retrospective data of 1,943 surgically treated pRCC patients from 17 European/ North American centers between 1984-2015 were compared to 5,600 ccRCC patients from a database comprising 11 European/ North American centers (1984-2011). Median follow-up was 64.6 months. Differences betwe…

Oncologymedicine.medical_specialtyMultidisciplinarybusiness.industryProportional hazards model030232 urology & nephrologyRetrospective cohort studymedicine.diseaseMetastasis03 medical and health sciencesClear cell renal cell carcinoma0302 clinical medicineRenal cell carcinoma030220 oncology & carcinogenesisInternal medicineCarcinomaMedicineCumulative incidenceStage (cooking)businessPLOS ONE
researchProduct

Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain

2019

Abstract Introduction The objective of the study was to determine the factors independently related with the development of castration resistance (CR) in prostate cancer (PC) in the medium term. Material and methods 155 patients diagnosed with metastatic PC with a follow-up of up to 39 months. Data taken from the National PC Registry. The evaluated variables were age, PSA, nadir PSA, Gleason, perineural invasion, TNM stages, and ADT type (intermittent / continuous). Results Mean follow-up 26,2 ± 13,4 months. 47.1% developed early CR, with mean time until onset of 12,2 ± 8,7 months. Univariate analysis: the mean PSA was correlated with CR (290 ± 905,1 ng/mL in non CR, 519,1 ± 1437,2 ng/mL in…

Oncologymedicine.medical_specialtyUnivariate analysisMultivariate analysisbusiness.industry030232 urology & nephrologyPerineural invasionGeneral Medicinemedicine.diseaseLower risk03 medical and health sciencesProstate cancer0302 clinical medicineCastration ResistanceInternal medicineTumor stagemedicinebusinessNadir (topography)Actas Urológicas Españolas (English Edition)
researchProduct

Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study

2021

Abstract Background Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) play a decisive role as prognostic markers in clear-cell renal cell carcinoma (RCC). To date, the role of PD-1/PD-L1 as a prognostic marker in papillary RCC (pRCC) remains scarce. Patients and Methods Patients’ sample collection was a joint collaboration of the nationwide PANZAR consortium – a multicenter study. Medical history and tumor specimens were collected from 245 and 129 patients with pRCC types 1 and 2, respectively. Expression of PD-1 and PD-L1 was determined by immunohistochemistry in pRCC and tumor-infiltrating mononuclear cells. Results Of 374 pRCC specimens, 204 type 1 and 97 type 2 we…

Oncologymedicine.medical_specialtyUrologyProgrammed Cell Death 1 Receptor030232 urology & nephrology610DiseaseB7-H1 Antigen03 medical and health sciences0302 clinical medicineRenal cell carcinomaInternal medicinePD-L1Biomarkers TumormedicineHumansMedical historyCarcinoma Renal CellPapillary renal cell carcinomasbiologybusiness.industryPrognosismedicine.diseaseKidney NeoplasmsOncology030220 oncology & carcinogenesisCohortbiology.proteinImmunohistochemistrySample collectionbusinessClinical Genitourinary Cancer
researchProduct

Risk factors and molecular characterization of penile cancer

2020

Purpose of review To provide a comprehensive summary of risk factors, molecular machinery as well as potential therapeutic targets with a particular focus on literature published in the last 2 years on prognosis and treatment of penile cancer (PeCa). Recent findings E2F, LAMC2, MAML2, ID1 and IGFBP2 proteins were demonstrated to play a critical role for aggressive tumor behavior and might predict poor survival in PeCa. PD-L1 axis was confirmed as a promising pathway to serve as a therapeutic target. A number of genetic alterations were illuminated. In clinical testing, pan-HER tyrosine kinase inhibitor dacomitinib provided promising results in chemo-naive and EGFR monoantibody nimotuzumab i…

Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classUrology030232 urology & nephrologyIndividualized treatmentmedicine.diseaseSystemic therapyDacomitinibTyrosine-kinase inhibitorClinical trial03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisInternal medicineMonoclonalmedicineNimotuzumabPenile cancerbusinessmedicine.drugCurrent Opinion in Urology
researchProduct

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

2020

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection wa…

Oncologymedicine.medical_specialtymedicine.medical_treatmentNeuroendocrine Carcinoma (NEC)030232 urology & nephrologylcsh:MedicineDiseaseSmall-cell carcinomaArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinedisease-specific survivalStage (cooking)prognostic factorbladdersmall cell carcinomaChemotherapyPerformance statusbusiness.industryPoorly differentiatedlcsh:Rprognostic factorsRetrospective cohort studyGeneral Medicinemedicine.diseaseperioperative chemotherapy030220 oncology & carcinogenesisCohortbusinessbladder; disease-specific survival; neuroendocrine carcinoma (nec); perioperative chemotherapy; prognostic factors; small cell carcinomaJournal of Clinical Medicine
researchProduct

Direct nucleation of calcium oxalate dihydrate crystals onto the surface of living renal epithelial cells in culture

1998

Direct nucleation of calcium oxalate dihydrate crystals onto the surface of living renal epithelial cells in culture. Background. The interaction of the most common crystal in human urine, calcium oxalate dihydrate (COD), with the surface of monkey renal epithelial cells (BSC-1 line) was studied to identify initiating events in kidney stone formation. Methods. To determine if COD crystals could nucleate directly onto the apical cell surface, a novel technique utilizing vapor diffusion of oxalic acid was employed. Cells were grown to confluence in the inner four wells of 24-well plates. At the start of each experiment, diethyloxalate in water was placed into eight adjacent wells, and the pla…

Oxalic acid030232 urology & nephrologyCalcium oxalateNucleationchemistry.chemical_elementApical cellCalciumKidneyOxalateCell LineCell membrane03 medical and health scienceschemistry.chemical_compoundKidney Calculi0302 clinical medicineDogsmedicineAnimalscrystallography030304 developmental biology0303 health sciencesKidneyx-ray of kidney calculiCalcium OxalateEpithelial CellsAnatomyHaplorhinimodels of stonesmedicine.anatomical_structurechemistryNephrologyBiophysicsstructural defectsCrystallizationcell membraneKidney International
researchProduct

Mandibular Brown Tumor as a Result of Secondary Hyperparathyroidism: A Case Report with 5 Years Follow-Up and Review of the Literature

2021

Background: Brown tumor is a rare skeletal manifestation of secondary hyperparathyroidism. Although diagnosis of the disease is increasingly seen in early stages due to improved screening techniques, some patients still present in a progressed disease stage. The treatment depends on tumor mass and varies from a conservative approach with supportive parathyroidectomy to extensive surgical resection with subsequent reconstruction. Case presentation: We report a case of extensive mandibular brown tumor in a patient with a history of systemic lupus erythematosus, chronic kidney disease, and secondary hyperparathyroidism. Following radical resection of the affected bone, reconstruction could be …

Parathyroidectomymedicine.medical_specialtyHealth Toxicology and Mutagenesismedicine.medical_treatment030232 urology & nephrologyCase Reportradical resectionDiseaseFree flap03 medical and health sciencesjaw0302 clinical medicinesecondary hyperparathyroidismmedicineStage (cooking)microvascular reconstructionbusiness.industryRPublic Health Environmental and Occupational Health030206 dentistrymedicine.diseasebrown tumorSurgeryBrown tumorMedicineSecondary hyperparathyroidismbusinessRadical resectionKidney diseaseInternational Journal of Environmental Research and Public Health
researchProduct

Renal papillary necrosis, an endoscopic vision.

2019

Renal papillary necrosis is described as an ischemic or chemical lesion at the end of the Malpighi pyramid, which causes the necrosis, with detachment and expulsion of the papilla in the urine. It ...

Pathologymedicine.medical_specialtyNecrosisUrology030232 urology & nephrologyHydronephrosis030204 cardiovascular system & hematologyRenal papillary necrosisLesion03 medical and health sciences0302 clinical medicinestomatognathic systemX ray computedUreteroscopyMedicineHumansDiabetic Nephropathiesintegumentary systemurogenital systembusiness.industryfood and beveragesUrographyMiddle Agedmedicine.diseaseMajor duodenal papillaDiabetes Mellitus Type 2NephrologyFemaleKidney Papillary Necrosismedicine.symptombusinessTomography X-Ray ComputedPyelogramScandinavian journal of urology
researchProduct

Primary Mucinous Adenocarcinoma of the Urinary Bladder with Signet-Ring Cells: Description of an Uncommon Case and Critical Points in Its Management

2016

We present an uncommon case of mucinous adenocarcinoma of the bladder (MAB) with signet-ring cells extensively infiltrating prostate gland and pelvic/retroperitoneal lymph node stations and not responsive to usual systemic chemotherapy regimens. This case highlights the important features of MAB including the pattern of tumor spread, the tendency for initial misdiagnosis, and the importance of immunohistochemical study in order to define its primary origin from the bladder and choose the most appropriate treatment since the beginning.

Pathologymedicine.medical_specialtyUrinary bladderSignet ring cellSystemic chemotherapybusiness.industryRetroperitoneal Lymph Node030232 urology & nephrologyCase ReportGeneral Medicinemedicine.diseaselcsh:Diseases of the genitourinary system. Urologylcsh:RC870-92303 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesismedicineAdenocarcinomaImmunohistochemistryProstate glandbusinessCase Reports in Urology
researchProduct